Skip to main content
SpringerLink
Log in

Economic and Quality-of-Life Aspects of Treating Small Cell Lung Cancer

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Aaronson NK. Assessing the quality of life of patients in cancer clinical trials: common problems and common sense solutions. European Journal of Cancer 28: 1304–1307, 1992

    Article  Google Scholar 

  • Barth N, Sferruza A, Akahoshi M, Allen K, Ditmore K. Administration of high dose chemotherapy (HDC) and autologous stem cells (ASC) in the outpatient setting. Abstract. Proceedings of the American Society of Clinical Oncology II: 389, 1992

    Google Scholar 

  • Bayliss EJ, Trotter JM. The cost of small cell lung cancer (SCLC). Abstract. Cancer Forum 14: 111, 1990

    Google Scholar 

  • Bergman B, Sullivan M, Sorenson S. Quality of life during chemotherapy for small cell lung cancer. Acta Oncologica 30: 947–957, 1991

    Article  PubMed  CAS  Google Scholar 

  • Carney DN. The biology of lung cancer. In Nunn (Ed.) European School of Oncology monographs: current topics in lung cancer, Springer-Verlag, Berlin Heidelberg, 1991

    Google Scholar 

  • Casliglione M, Bacchi M, Metzger U, Senn HJ. Quality of life in melaslic breast cancer: comparing perceptions of patients and nurses. Abstract. Proceedings of the American Society of Clinical Oncology II: 54, 1992

    Google Scholar 

  • Clark PI, Slevin ML. Small cell lung cancer: single agents revisited. Respiratory Medicine 3: 381–382, 1989

    Article  Google Scholar 

  • Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 325: 164–170, 1991

    Article  PubMed  CAS  Google Scholar 

  • Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in canter patients. Journal of Clinical Oncology 7: 959–968, 1989

    PubMed  CAS  Google Scholar 

  • Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, et al. A randomised trial of as planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 64: 566–572, 1991

    Article  PubMed  CAS  Google Scholar 

  • Evans DB. What is cost-effectiveness analysis. Medical Journal of Australia 153(Suppl.): 7–9, 1990a

    Google Scholar 

  • Evans DB. Principles involved in costing. Medical Journal of Australia 153(Suppl.): 10–12, 1990b

    Google Scholar 

  • Fayers P. Quality-of-life assessments in small cell lung cancer. PharmacoEconomics 2: 181–188, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ganz PA, Haskell CM, Figlin A, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky Performance Status and the Functional Living Index-Cancer. Cancer 61: 849–856, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gelber RD, Goldhirsch A. A new end point for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology 4: 1772–1779, 1986

    PubMed  CAS  Google Scholar 

  • Glasziou PP, Simes J, Gelber RD. Quality-adjusted survival analysis. Statistics in Medicine 9: 1259–1276, 1990

    Article  PubMed  CAS  Google Scholar 

  • Goldhirsch A, Gelber RD, Simes J, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. Journal of Clinical Oncology. 7: 36–44, 1989

    PubMed  CAS  Google Scholar 

  • Goldman L. Cost awareness in medicine. In Wilson et al. (Eds) Harrison’s principles of internal medicine, pp. 11–15, McGraw-Hill, New York, NY, USA, 1990

    Google Scholar 

  • Goodwin PJ, Feld R, Evans WK., Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomised trial in small-cell lung cancer. Journal of Clinical Oncology 6: 1537–1547, 1988

    PubMed  CAS  Google Scholar 

  • Gotay CC, Korn EC, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. Journal of the National Cancer Institute 84: 575–578, 1992

    Article  PubMed  CAS  Google Scholar 

  • Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. American Journal of Medicine 40: 360–367, 1969

    Google Scholar 

  • Hanks GE. The crisis in health care cost in the United States: some implications for radiation oncology. International Journal of Radiation, Biology and Physics 23: 203–206, 1992

    Article  CAS  Google Scholar 

  • Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. Journal of the American Medical Association 267: 2055–2061, 1992

    Article  PubMed  CAS  Google Scholar 

  • Houtts PS, Lipton A, Harvey HA, Martin B, Simmonds MA et al. Non medical costs to patients and their families associated with outpatient chemotherapy. Cancer 53: 2388–2392, 1984

    Article  Google Scholar 

  • Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung; a randomised study. Journal of Clinical Oncology 5: 1864–1873, 1987

    PubMed  CAS  Google Scholar 

  • Hyde L, Wolf J, McCracken S, Yesner R. Natural course of inoperable lung cancer. Chest 64: 309–312, 1973

    Article  PubMed  CAS  Google Scholar 

  • Johnson PWM, Seymour MT, Waines A, Squires L, Slevin ML. Etoposide as a single agent in small cell lung cancer (SCLC): as good as combination chemotherapy? Proceedings of the American Society of Clinical Oncology 11: 291, 1992

    Google Scholar 

  • Langlands A. Cost effectiveness or catch 22? Medical Journal of Australia 157: 6–7, 1992

    PubMed  CAS  Google Scholar 

  • Langlands AO. The evaluation of the results of cancer therapy; treatment utility. Australian and New Zealand Journal of Surgery 51: 10–12, 1981

    Article  PubMed  CAS  Google Scholar 

  • Lowenbraun S, la Rocca RV. Neutrophil count-directed G-CSF administration following chemotherapy. Abstract. Proceedings of the American Society of Clinical Oncology II: 401, 1992

    Google Scholar 

  • McGivney WT. Proposal for assuring technology competency and leadership in medicine. Journal of the National Cancer Institute 84: 742–743, 1992

    Article  PubMed  CAS  Google Scholar 

  • McKillop WJ, Gard GK, O’Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small-cell lung cancer. British Journal of Cancer 54: 661–667, 1986

    Article  Google Scholar 

  • McVie JG. Counting costs of care. Journal of Clinical Oncology 6: 1529–1531, 1988

    PubMed  CAS  Google Scholar 

  • Medical Research Council Lung Cancer Working Party. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. British Journal of Cancer 64: 299–306, 1991

    Google Scholar 

  • Medical Research Council Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Respiratory Medicine 83: 51–58, 1989a

  • Medical Research Council Lung Cancer Working Party. Controlled trial of twelve vs six courses of chemotherapy in the treatment of smali-cell lung cancer. British Journal of Cancer 59: 584–590, 1989b

  • Minna JD, Pass H, Glatstein E, Ihde DC. Cancer of the Lung. In De Vita (Ed.) Cancer principles and practice of oncology, 3rd ed., JB Lippincott Co., Philadelphia, 1989

    Google Scholar 

  • Osterlind K, Anderson PK. Prognostic factors in small cell lung cancer: multivariate analysis based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46: 4189–4194, 1986

    PubMed  CAS  Google Scholar 

  • Richardson GE, Venzon DJ, Steinberg SM, Phelps R, Frame JN, et al. An algorithm for staging patients with small cell lung cancer (SCLC) can save 40% of the initial evaluation costs. Abstract. Proceedings of the American Society of Clinical Oncology 10: 242, 1991

    Google Scholar 

  • Rosenthal MA, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, et al. The cost of treating small cell lung cancer. Medical Journal of Australia 156: 605–610, 1992

    PubMed  CAS  Google Scholar 

  • Sheehan RG, Balaban EP, Cox JV, Frenkel EP. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer. Journal of Clinical Oncology 8: 2047–2053, 1990

    PubMed  CAS  Google Scholar 

  • Silverberg E. Cancer statistics, 1988. CA 38: 5–22, 1988

    CAS  Google Scholar 

  • Souadjian JV, Bhaskar B, Briscoe KE, Opfell RW, Agopian JM. Home chemotherapy (CT): safety and cost-effectiveness. Proceedings of the American Society of Clinical Oncology 11: 410, 1992

    Google Scholar 

  • Spiegelman D, Mauer LH, Ware JH, Perry MC, Chatnnian P, et al. Prognostic factors in small cell lung carcinoma of the lung: an analysis of 1521 patients. Journal of Clinical Oncology 7: 344–354, 1989

    PubMed  CAS  Google Scholar 

  • Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small-cell carcinoma of the lung? A meta-analysis. Journal of Clinical Oncology 10: 890–895, 1992

    PubMed  CAS  Google Scholar 

  • Wolf M, Prtsch M, Drings P, Hans K, Scbroeder M, et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomised trial of 321 patients. Journal of Clinical Oncology 9: 614–624, 1991

    PubMed  CAS  Google Scholar 

  • Zelen M. Keynote address on bioslatistics and data retrieval. Cancer Chemotherapy Reports 4(part 3): 31–42, 1973

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales, 2145, Australia

    P. Graham &  J. Boyages (Senior Staff Specialist)

Authors
  1. P. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Boyages
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graham, P., Boyages, J. Economic and Quality-of-Life Aspects of Treating Small Cell Lung Cancer. Pharmacoeconomics 3, 446–453 (1993). https://doi.org/10.2165/00019053-199303060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199303060-00004

Keywords

Search

Navigation